Mavodelpar + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Mitochondrial Myopathy
Conditions
Primary Mitochondrial Myopathy
Trial Timeline
May 21, 2021 → Oct 5, 2023
NCT ID
NCT04535609About Mavodelpar + Placebo
Mavodelpar + Placebo is a phase 2 stage product being developed by OnKure Therapeutics for Primary Mitochondrial Myopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04535609. Target conditions include Primary Mitochondrial Myopathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04535609 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Mitochondrial Myopathy